{"result": {"id": "749696ba-10bb-46da-bdec-96f3d0f265f7", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>VASC BIOL<|>ORGANIZATION<|>Vasc Biol is a journal that publishes research on vascular biology and related topics.\")\n##\n(\"entity\"<|>VA VLUKIS M<|>PERSON<|>Vavlukis M is a researcher who contributed to a study on adding ezetimibe to statin therapy.\")\n##\n(\"entity\"<|>VA VLUKIS A<|>PERSON<|>Vavlukis A is a researcher who contributed to a study on adding ezetimibe to statin therapy.\")\n##\n(\"entity\"<|>CAI SY<|>PERSON<|>Cai SY is a researcher involved in a clinical trial on hybutimibe monotherapy or combination with atorvastatin.\")\n##\n(\"entity\"<|>GU X<|>PERSON<|>Gu X is a researcher involved in a clinical trial on hybutimibe monotherapy or combination with atorvastatin.\")\n##\n(\"entity\"<|>LIU PJ<|>PERSON<|>Liu PJ is a researcher involved in a clinical trial on hybutimibe monotherapy or combination with atorvastatin.\")\n##\n(\"entity\"<|>AGUILAR-SALINAS CA<|>PERSON<|>Aguilar-Salinas CA is a researcher who contributed to a study on new therapies for primary hyperlipidemia.\")\n##\n(\"entity\"<|>GÓMEZ-DÍAZ RA<|>PERSON<|>Gómez-Díaz RA is a researcher who contributed to a study on new therapies for primary hyperlipidemia.\")\n##\n(\"entity\"<|>CORRAL P<|>PERSON<|>Corral P is a researcher who contributed to a study on new therapies for primary hyperlipidemia.\")\n##\n(\"entity\"<|>BARALE C<|>PERSON<|>Barale C is a researcher who contributed to a study on PCSK9 biology and its role in atherothrombosis.\")\n##\n(\"entity\"<|>MELCHIONDA E<|>PERSON<|>Melchionda E is a researcher who contributed to a study on PCSK9 biology and its role in atherothrombosis.\")\n##\n(\"entity\"<|>MOROTTI A<|>PERSON<|>Morotti A is a researcher who contributed to a study on PCSK9 biology and its role in atherothrombosis.\")\n##\n(\"entity\"<|>MOMTAZI-BOROJENI AA<|>PERSON<|>Momtazi-Borojeni AA is a researcher who contributed to a study on PCSK9 and inflammation.\")\n##\n(\"entity\"<|>SABOURI-RAD S<|>PERSON<|>Sabouri-Rad S is a researcher who contributed to a study on PCSK9 and inflammation.\")\n##\n(\"entity\"<|>GOTTO AM<|>PERSON<|>Gotto AM is a researcher who contributed to a study on PCSK9 and inflammation.\")\n##\n(\"entity\"<|>RAY KK<|>PERSON<|>Ray KK is a researcher involved in phase 3 trials of inclisiran in patients with elevated LDL cholesterol.\")\n##\n(\"entity\"<|>WRIGHT RS<|>PERSON<|>Wright RS is a researcher involved in phase 3 trials of inclisiran in patients with elevated LDL cholesterol.\")\n##\n(\"entity\"<|>KALLEND D<|>PERSON<|>Kallend D is a researcher involved in phase 3 trials of inclisiran in patients with elevated LDL cholesterol.\")\n##\n(\"entity\"<|>XU J<|>PERSON<|>Xu J is a researcher involved in a study comparing Xuezhikang and pravastatin effects on triglyceride levels.\")\n##\n(\"entity\"<|>ZHU L<|>PERSON<|>Zhu L is a researcher involved in a study comparing Xuezhikang and pravastatin effects on triglyceride levels.\")\n##\n(\"entity\"<|>XIE Y<|>PERSON<|>Xie Y is a researcher involved in a study comparing Xuezhikang and pravastatin effects on triglyceride levels.\")\n##\n(\"entity\"<|>LU Z<|>PERSON<|>Lu Z is a researcher involved in a study on the effect of Xuezhikang on coronary events.\")\n##\n(\"entity\"<|>KOU W<|>PERSON<|>Kou W is a researcher involved in a study on the effect of Xuezhikang on coronary events.\")\n##\n(\"entity\"<|>DU B<|>PERSON<|>Du B is a researcher involved in a study on the effect of Xuezhikang on coronary events.\")\n##\n(\"entity\"<|>CHINESE GERONTOLOGY AND GERIATRICS SOCIETY<|>ORGANIZATION<|>The Chinese Gerontology and Geriatrics Society is an organization involved in cardiovascular disease research and consensus development.\")\n##\n(\"relationship\"<|>VA VLUKIS M<|>VA VLUKIS A<|>Vavlukis M and Vavlukis A co-authored a study on adding ezetimibe to statin therapy.<|>8\")\n##\n(\"relationship\"<|>CAI SY<|>GU X<|>Cai SY and Gu X co-authored a clinical trial on hybutimibe monotherapy or combination with atorvastatin.<|>8\")\n##\n(\"relationship\"<|>CAI SY<|>LIU PJ<|>Cai SY and Liu PJ co-authored a clinical trial on hybutimibe monotherapy or combination with atorvastatin.<|>8\")\n##\n(\"relationship\"<|>GU X<|>LIU PJ<|>Gu X and Liu PJ co-authored a clinical trial on hybutimibe monotherapy or combination with atorvastatin.<|>8\")\n##\n(\"relationship\"<|>AGUILAR-SALINAS CA<|>GÓMEZ-DÍAZ RA<|>Aguilar-Salinas CA and Gómez-Díaz RA co-authored a study on new therapies for primary hyperlipidemia.<|>8\")\n##\n(\"relationship\"<|>AGUILAR-SALINAS CA<|>CORRAL P<|>Aguilar-Salinas CA and Corral P co-authored a study on new therapies for primary hyperlipidemia.<|>8\")\n##\n(\"relationship\"<|>GÓMEZ-DÍAZ RA<|>CORRAL P<|>Gómez-Díaz RA and Corral P co-authored a study on new therapies for primary hyperlipidemia.<|>8\")\n##\n(\"relationship\"<|>BARALE C<|>MELCHIONDA E<|>Barale C and Melchionda E co-authored a study on PCSK9 biology and its role in atherothrombosis.<|>8\")\n##\n(\"relationship\"<|>BARALE C<|>MOROTTI A<|>Barale C and Morotti A co-authored a study on PCSK9 biology and its role in atherothrombosis.<|>8\")\n##\n(\"relationship\"<|>MELCHIONDA E<|>MOROTTI A<|>Melchionda E and Morotti A co-authored a study on PCSK9 biology and its role in atherothrombosis.<|>8\")\n##\n(\"relationship\"<|>MOMTAZI-BOROJENI AA<|>SABOURI-RAD S<|>Momtazi-Borojeni AA and Sabouri-Rad S co-authored a study on PCSK9 and inflammation.<|>8\")\n##\n(\"relationship\"<|>MOMTAZI-BOROJENI AA<|>GOTTO AM<|>Momtazi-Borojeni AA and Gotto AM co-authored a study on PCSK9 and inflammation.<|>8\")\n##\n(\"relationship\"<|>SABOURI-RAD S<|>GOTTO AM<|>Sabouri-Rad S and Gotto AM co-authored a study on PCSK9 and inflammation.<|>8\")\n##\n(\"relationship\"<|>RAY KK<|>WRIGHT RS<|>Ray KK and Wright RS co-authored phase 3 trials of inclisiran in patients with elevated LDL cholesterol.<|>8\")\n##\n(\"relationship\"<|>RAY KK<|>KALLEND D<|>Ray KK and Kallend D co-authored phase 3 trials of inclisiran in patients with elevated LDL cholesterol.<|>8\")\n##\n(\"relationship\"<|>WRIGHT RS<|>KALLEND D<|>Wright RS and Kallend D co-authored phase 3 trials of inclisiran in patients with elevated LDL cholesterol.<|>8\")\n##\n(\"relationship\"<|>XU J<|>ZHU L<|>Xu J and Zhu L co-authored a study comparing Xuezhikang and pravastatin effects on triglyceride levels.<|>8\")\n##\n(\"relationship\"<|>XU J<|>XIE Y<|>Xu J and Xie Y co-authored a study comparing Xuezhikang and pravastatin effects on triglyceride levels.<|>8\")\n##\n(\"relationship\"<|>ZHU L<|>XIE Y<|>Zhu L and Xie Y co-authored a study comparing Xuezhikang and pravastatin effects on triglyceride levels.<|>8\")\n##\n(\"relationship\"<|>LU Z<|>KOU W<|>Lu Z and Kou W co-authored a study on the effect of Xuezhikang on coronary events.<|>8\")\n##\n(\"relationship\"<|>LU Z<|>DU B<|>Lu Z and Du B co-authored a study on the effect of Xuezhikang on coronary events.<|>8\")\n##\n(\"relationship\"<|>KOU W<|>DU B<|>Kou W and Du B co-authored a study on the effect of Xuezhikang on coronary events.<|>8\")\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166441, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 2181, "prompt_tokens": 2827, "total_tokens": 5008, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 1035}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Vasc Biol,        2019,         39 (2):       e38?81.         DOI:        10.1161/ ATV.0000000000000073.\n[42]      Vavlukis    M,    Vavlukis   A.    Adding    ezetimibe   to    statin therapy:    latest    evidence    and    clinical    implications[J]. Drugs     Context,     2018,     7:    212534.     DOI:      10.7573/ dic.212534.\n[43]      蔡思宇, 顾翔, 刘培晶, 等 . 海博麦布单药或联合阿托伐他 汀治疗原发性高胆固醇血症的疗效及安全性:多中心随机 双盲双模拟平行对照Ⅲ期临床研究[J].中华心血管病杂志, 2023,       51 (2):       180?187.        DOI:        10.3760/cma.      j. cn112148?20230105?00009.\n　Cai  SY,  Gu  X,  Liu  PJ,  et al.  Efficacy  and  safety  of  various doses of hybutimibe monotherapy or in combination with atorvastatin      for     primary      hypercholesterolemia:      a multicenter,   randomized,   double?blind,    double?dummy,\n\n\n\n中华全科医师杂志 2024 年 9 月第 23 卷第 9 期    Chin J Gen Pract, September 2024, Vol. 23, No. 9                                                                  · 917   ·\n\n\nparallel?controlled phase  Ⅲ clinical trial[J]. Chin J Cardiol, 2023,        51 (2):       180?187.       DOI:        10.3760/cma.      j. cn112148?20230105?00009.\n[44]      Aguilar?Salinas    CA,    Gómez?Díaz    RA,    Corral    P.    New therapies for primary hyperlipidemia[J]. J Clin Endocrinol Metab,     2022,      107 (5):    1216?1224.      DOI:     10.1210/ clinem/dgab876.\n[45]      Barale  C,  Melchionda  E,  Morotti  A,  et al.  PCSK9  biology and  its  role  in  atherothrombosis[J].  Int  J  Mol  Sci,  2021, 22 (11):5880. DOI: 10.3390/ijms22115880.\n[46]      Momtazi?Borojeni   AA,   Sabouri?Rad   S,   Gotto   AM,   et al. PCSK9  and  inflammation:  a  review  of  experimental  and clinical evidence[J]. Eur Heart J Cardiovasc Pharmacother, 2019, 5 (4):237?245.\n[47]       Ray KK, Wright RS, Kallend D, et al. Two phase  3 trials of inclisiran  in  patients with  elevated  LDL  cholesterol[J].  N Engl  J  Med,  2020,  382 (16): 1507?1519.  DOI:  10.1056/ NEJMoa1912387.\n[48]       Xu   J,   Zhu   L,   Xie   Y,   et al.    Effects   of   Xuezhikang   versus pravastatin on triglyceride level in patients with T2DM and dyslipidemia:  study  protocol  for  a  multicenter  randomized controlled    trial[J].    Curr    Vasc    Pharmacol,    2023,    21(3): 211?217. DOI: 10.2174/1570161121666230328110215.\n[49]       Lu Z, Kou W, Du  B, et al.  Effect  of Xuezhikang, an extract from  red  yeast  Chinese  rice,  on  coronary  events  in  a Chinese  population  with  previous  myocardial  infarction [J].   Am    J    Cardiol,    2008,    101 (12):   1689?1693.    DOI: 10.1016/j.amjcard.2008.02.056.\n[50]      中国老年学和老年医学学会心脑血管病专业委员会, 血脂 康(胶囊)临床应用中国专家共识组 . 血脂康(胶囊)临床应 用中国专家共识(2017 修订版) [J]. 中华内科杂志, 2018, 57 (2):            97?100.             DOI:             10.3760/cma.           j. issn.0578?1426.2018.02.003.\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_13b0c953b7dfda5d4b38029cc46dab55c07789dc7cbb09be924b0caecfbe415c_v2"}